↓ Skip to main content

Oncolytic viruses as therapeutic cancer vaccines

Overview of attention for article published in Molecular Cancer, September 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 1,419)
  • High Attention Score compared to outputs of the same age (93rd percentile)

Mentioned by

blogs
1 blog
twitter
7 tweeters
patent
4 patents
facebook
2 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
201 Dimensions

Readers on

mendeley
267 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Oncolytic viruses as therapeutic cancer vaccines
Published in
Molecular Cancer, September 2013
DOI 10.1186/1476-4598-12-103
Pubmed ID
Authors

David L Bartlett, Zuqiang Liu, Magesh Sathaiah, Roshni Ravindranathan, Zongbi Guo, Yukai He, Zong Sheng Guo

Abstract

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells via tumor vasculature targeting and bystander effect. Multimodal immunogenic cell death (ICD) together with autophagy often induced by OVs not only presents potent danger signals to dendritic cells but also efficiently cross-present tumor-associated antigens from cancer cells to dendritic cells to T cells to induce adaptive antitumor immunity. With this favorable immune backdrop, genetic engineering of OVs and rational combinations further potentiate OVs as cancer vaccines. OVs armed with GM-CSF (such as T-VEC and Pexa-Vec) or other immunostimulatory genes, induce potent anti-tumor immunity in both animal models and human patients. Combination with other immunotherapy regimens improve overall therapeutic efficacy. Coadministration with a HDAC inhibitor inhibits innate immunity transiently to promote infection and spread of OVs, and significantly enhances anti-tumor immunity and improves the therapeutic index. Local administration or OV mediated-expression of ligands for Toll-like receptors can rescue the function of tumor-infiltrating CD8+ T cells inhibited by the immunosuppressive tumor microenvironment and thus enhances the antitumor effect. Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 267 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 2 <1%
Malaysia 2 <1%
Austria 1 <1%
Indonesia 1 <1%
Colombia 1 <1%
Australia 1 <1%
Canada 1 <1%
Belgium 1 <1%
China 1 <1%
Other 0 0%
Unknown 256 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 67 25%
Student > Master 51 19%
Student > Ph. D. Student 44 16%
Researcher 40 15%
Student > Doctoral Student 12 4%
Other 32 12%
Unknown 21 8%
Readers by discipline Count As %
Agricultural and Biological Sciences 77 29%
Biochemistry, Genetics and Molecular Biology 59 22%
Medicine and Dentistry 47 18%
Immunology and Microbiology 31 12%
Pharmacology, Toxicology and Pharmaceutical Science 8 3%
Other 18 7%
Unknown 27 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2019.
All research outputs
#1,058,020
of 18,382,898 outputs
Outputs from Molecular Cancer
#28
of 1,419 outputs
Outputs of similar age
#10,978
of 173,662 outputs
Outputs of similar age from Molecular Cancer
#1
of 1 outputs
Altmetric has tracked 18,382,898 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,419 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,662 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them